Paricalcitol
产品说明书
 |
同义名 : | 1α,25-Dihydroxy-19-nor-vitamin D2;Zemplar;paricalcitol-d6;Abbott brand of paricalcitol;Paracalcin;19-Nor-1alpha,25-dihydroxyvitamin D2;Compound 49510;19-nor-1,25-Dihydroxyvitamin D2 |
| CAS号 : | 131918-61-1 | |
| 货号 : | A494988 | |
| 分子式 : | C27H44O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 416.637 | |
| MDL号 : | MFCD08067734 | |
| 存储条件： |
Pure form Sealed in dry,Store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(252.02 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 12.5 mg/mL(30 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Paricalcitol is a vitamin D receptor agonist, used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01204528 | Chronic Kidney Disease | Phase 2 Phase 3 | Completed | - | Sweden ... 展开 >> Karolinska Institute at Danderyd University Hospital Danderyd, Stockholm, Sweden, 18288 收起 << |
| NCT02018133 | CKD Stage 3/4 | Phase 3 | Completed | - | United States, Illinois ... 展开 >> University of Illinois at Chicago Chicago, Illinois, United States, 60612 收起 << |
| NCT03138720 | Resectable Pancreatic Cancer ... 展开 >> Unresectable Pancreatic Cancer Pancreatic Adenocarcinoma 收起 << | Phase 2 | Recruiting | March 1, 2020 | United States, Arizona ... 展开 >> HonorHealth Research Institute Recruiting Scottsdale, Arizona, United States, 85258 Contact: Joyce Schaffer, MSN, AOCNS 480-323-1339 ext option #2 Joyce.Schaffer@HonorHealth.com Principal Investigator: Erkut Borazanci, MD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.40mL 0.48mL 0.24mL |
12.00mL 2.40mL 1.20mL |
24.00mL 4.80mL 2.40mL |
| 参考文献 |
|---|